Use and adherence to beta-blockers for secondary prevention of myocardial infarction: Who is not getting the treatment?

Pharmacoepidemiology and Drug Safety

Volumn 13, Issue 11, 2004, Pages 761-766

  Wei, Li ^a   Flynn, Robert ^a,b   Murray, Gordon D ^b   McDonald, Thomas M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Adherence; Beta blockers; Mortality; Post MI

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; NITRATE; STEROID; THIAZIDE DIURETIC AGENT;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; DIABETES MELLITUS; DRUG EXPOSURE; DRUG USE; FEMALE; GENDER; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; NONBIOLOGICAL MODEL; OBSERVATION; OBSTRUCTIVE AIRWAY DISEASE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RECURRENT DISEASE; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SOCIAL ISOLATION; SURVIVAL TIME; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT COMPLIANCE; RECURRENCE; SCOTLAND;

EID: 8644253683     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.963     Document Type: Article

References (29)

1. Freemantle, N, Cleland J, Young P, Mason J, Harrison J. Beta Blockade after myocardial infarction: systematic review and meta regression analysis. Br Med J 1999; 318: 1730-1737.
2. Kennedy HL. Current utilization trends for beta-blockers in cardiovascular disease. Am J Med 2001; 110 (5A): 2S-6S.
3. MacDonald TM, Butler R, Newton RW, Morris AD. Which drugs benefit diabetic patients for secondary prevention of myocardial infarction? Diabet Med 1998; 15: 282-289.
4. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489-497.
5. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995-1001.
6. Gottlieb SS. Underuse of beta-blockers in cardiovascular medicine. Am J Manag Care 2000; 2(Suppl.): S299-S302.
7. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002; 288: 2868-2879.
8. Evans JMM, MacDonald TM. The tayside medicines monitoring unit (MEMO). In Pharmacoepidemiology, 3rd edn, Strom BL (ed.). John Wiley and Sons: Chichester, 2000; 361-374.
9. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-763.
10. Bowker TJ, Clayton TC, Ingham J, et al. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (action on secondary prevention through intervention to reduce events). Heart 1996; 75: 334-342.
11. Nicholls SJ, McElduff P, Dobson AJ, Jamrozik KD, Hobbs MS, Leitch JW. Underuse of beta-blockers following myocardial infarction: a tale of two cities. Intern Med J 2001; 31: 391-396.
12. Bradley EH, Holmboe ES, Mattera JA, Roumanis SA, Radford MJ, Krumbolz HM. A qualitative study of increasing beta-blocker use after myocardial infarction: why do some hospitals succeed? JAMA 2001; 285: 2604-2611.
13. Beck CA, Lauzon C, Eisenberg MJ, et al. Discharge prescriptions following admission for acute myocardial infarction at tertiary care and community hospitals in Quebec. Can J Cardiol 2001; 17: 33-40.
14. Avanzini F, Zuanetti G, Latini R, et al. Use of beta-blocking agents in secondary prevention after myocardial infarction: a case for evidence-based medicine? GISSI experience, 1984-1993. The Gruppo Italiano di Studio sulla Sopravvivenza nel-l'Infarto Miocardico (GISSI) investigators. Eur Heart J 1997; 18:1447-1456.
15. Suresh V, Harrison RA, Houghton P, Naqvi N. Standard cardiac rehabilitation is less effective for diabetics. Int J Clin Pract 2001; 55: 445-448.
16. Sial SH, Malone M, Freeman JL, Battiola R, Nachodsky J, Goodwin JS. Beta blocker use in the treatment of community hospital patients discharged after myocardial infarction. J Gen Intern Med 1994; 9: 599-605.
17. Wu AH, Parsons L, Every NR, Bates ER. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 2002; 40: 1389-1394.
18. Younis N, Burnham P, Patwala A, Weston PJ, Vora JP. Beta blocker prescribing differences in patients with and without diabetes following a first myocardial infarction. Diabet Med 2001; 18: 159-161.
19. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385-1390.
20. Spargias KS, Hall AS, Greenwood DC, Ball SG. Beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study. Heart 1999; 81: 25-32.
21. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001; 37: 1950-1956.
22. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002; 88: 229-233.
23. Butler J, Arbogast PG, BeLue R, et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol 2002; 40: 1589-1595.
24. Mitra S, Findley K, Frohnapple D, Mehta JL. Trends in long-term management of survivors of acute myocardial infarction by cardiologists in a government university-affiliated teaching hospital. Clin Cardiol 2002; 25: 16-18.
25. Gallagher EJ, Viscoli CM, Horwitz RI. The relationship of treatment adherence to the risk of death after myocardial infarction in women. JAMA 1993; 270: 742-744.
26. Scottish health survey 1995 (vol. 1: chapter 4 Smoking). The Stationary Office: Edinburgh, 1997; 140-141.
27. Evans JM, Newton RW, Ruta DA, MacDonald TM, Morris AD. Socio-economic status, obesity and prevalence of Type 1 and Type 2 diabetes mellitus. Diabet Med 2000; 17: 478-480.
28. Davis BS, McWhirter MF, Gordon DS. Where needs and demands diverge: health promotion in primary care. Public Health 1996; 110: 95-101.
29. MacDonald TM, Morant SV, Robinson GC, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. Br Med J 1997; 315: 1333-1337.